Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

This is an interventional treatment trial for NAFLD - Nonalcoholic Fatty Liver Disease Read More

Inclusion Criteria:

• Men or women aged 19 years or over, under 75 years
• A person diagnosed with nonalcoholic fatty liver in abdominal ultrasound (abdominal ultrasound can be substituted if there is a diagnosis of fatty liver through ultrasound within 1 year), or a person diagnosed with fatty liver in abdominal ultrasonography through screening because of clinical suspicion of fatty liver
• Patients who are diagnosed with type 2 diabetes and who are treated with oral medication, excluding TZD or SGLT2i drug users within the last 12 weeks
• Those who have voluntarily agreed in written form to participate in the clinical trial after hearing the explanation of this clinical trial
• Those who understand the content of the clinical trial and are able to participate in the trial until the end of the clinical trial

Exclusion Criteria:

• Diabetic patients other than type 2 diabetes, including type 1 diabetes and gestational diabetes
• Type 2 diabetic patients undergoing insulin therapy
• Patients who have taken TZD or SGLT2i drugs within the last 12 weeks or have had a history of severe side effects after taking the above drugs
• Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, and those with a history of ketone phosphatemia (within 6 months)
• Patients who meet the criteria for alcoholic liver disease (210 g / week for men in the last two years, 140 g / week for women)
• People who take drugs that can cause fatty liver (amiodarone, methotrexate, tamoxifen, valproate, etc.)
• Allergic or hypersensitive to the drug or its constituents
• Patients receiving oral or parenteral corticosteroid therapy chronic (within consecutive 14 days) within 8 weeks prior to screening require continual changes in corticosteroid dosage for therapeutic purposes
• Patients with genetic problems such as galactosemia, Lapp lactase deficiency or glucose-galactose uptake
• Malignant tumors that are currently undergoing treatment or progressive
• Patients with a history of substance abuse or alcohol intoxication within 12 weeks
• Human immunodeficiency virus (HIV)
• Patients with severe infection, pre- and post-operative, and severe trauma
• Patients with cardiac failure within 6 months (class III to IV in the NYHA classification)
• Patients with acute cardiovascular disease within 12 weeks (patients with unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass grafting, or coronary intervention)
• People with renal failure, chronic renal disease (estimated glomerular filtration rate <45 mL / min / 1.73 m2) or those who are difficult to use the medication due to dialysis
• Pregnant or lactating women
• A person who the examiner considers not eligible for clinical trials